This Article Full Text Full Text (PDF) All Versions of this Article: 120/7/577    most recent CIRCULATIONAHA.108.847772v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Weidemann, F. Articles by Strotmann, J. M. PubMed PubMed Citation Articles by Weidemann, F. Articles by Strotmann, J. M. Related Collections Contractile function Echocardiography CV surgery: aortic and vascular disease Related Article

(Circulation. 2009;120:577-584.)
© 2009 American Heart Association, Inc.

Imaging

Impact of Myocardial Fibrosis in Patients With Symptomatic Severe Aortic Stenosis

Frank Weidemann, MD^*; Sebastian Herrmann^*; Stefan Störk, MD; Markus Niemann, MD; Stefan Frantz, MD; Volkmar Lange, MD; Meinrad Beer, MD; Stefan Gattenlöhner, MD; Wolfram Voelker, MD; Georg Ertl, MD; Jörg M. Strotmann, MD

From the University Clinic of Internal Medicine I/Center for Cardiovascular Disease (F.W., S.H., S.S., M.N., S.F., W.V., G.E., J.M.S.), Clinic for Heart Surgery (V.L.), Clinic for Radiology (M.B.), and Institute of Pathology (S.G.), University of Würzburg, Würzburg, Germany.

Correspondence to Frank Weidemann, MD, Medizinische Klinik und Poliklinik I, Universität Würzburg, Josef-Schneider-Str 2, 97080 Würzburg, Germany. E-mail Weidemann_f{at}medizin.uni-wuerzburg.de

Received December 30, 2008; accepted June 5, 2009.

Background— In this prospective follow-up study, the effect of myocardial fibrosis on myocardial performance in symptomatic severe aortic stenosis was investigated, and the impact of fibrosis on clinical outcome after aortic valve replacement (AVR) was estimated.

Methods and Results— Fifty-eight consecutive patients with isolated symptomatic severe aortic stenosis underwent extensive baseline characterization before AVR. Standard and tissue Doppler echocardiography and cardiac magnetic resonance imaging (late-enhancement imaging for replacement fibrosis) were performed at baseline and 9 months after AVR. Endomyocardial biopsies were obtained intraoperatively to determine the degree of myocardial fibrosis. Patients were analyzed according to the severity of interstitial fibrosis in cardiac biopsies (severe, n=21; mild, n=15; none, n=22). The extent of histologically determined cardiac fibrosis at baseline correlated closely with New York Heart Association functional class and markers of longitudinal systolic function (all P<0.001) but not global ejection fraction or aortic valve area. Nine months after AVR, the degree of late enhancement remained unchanged, implying that AVR failed to reduce the degree of replacement fibrosis. Patients with no fibrosis experienced a marked improvement in New York Heart Association class from 2.8±0.4 to 1.4±0.5 (P<0.001). Only parameters of longitudinal systolic function predicted this functional improvement. Four patients with severe fibrosis died during follow-up, but no patient from the other groups died.

Conclusions— Myocardial fibrosis is an important morphological substrate of postoperative clinical outcome in patients with severe aortic stenosis and was not reversible after AVR over the 9 months of follow-up examined in this study. Because markers of longitudinal systolic function appear to indicate sensitively both the severity of myocardial fibrosis and the clinical outcome, they may prove valuable for preoperative risk assessment in patients with aortic stenosis.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2009 120: 543-545. [Extract] [Full Text]